OVID Key Statistics, Chart & Performance
The current stock price of OVID is 1.785 USD. In the past month the price increased by 29.93%. In the past year, price increased by 56.14%.
OVID Latest News, Press Relases and Analysis
OVID Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.79 | 397.32B | ||
| AMGN | AMGEN INC | 15.5 | 182.52B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.74B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.65 | 108.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.89 | 79.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 896.28 | 60.39B | ||
| INSM | INSMED INC | N/A | 44.58B | ||
| NTRA | NATERA INC | N/A | 32.90B | ||
| BIIB | BIOGEN INC | 10.61 | 26.05B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.16 | 20.64B | ||
| INCY | INCYTE CORP | 15.9 | 20.04B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B |
Related stock screener links
About OVID
Company Profile
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Company Info
OVID THERAPEUTICS INC
441 Ninth Avenue, 14Th Floor
New York City NEW YORK 10036 US
CEO: Jeremy M. Levin
Employees: 23
Phone: 12127764381
OVID THERAPEUTICS INC / OVID FAQ
Can you describe the business of OVID THERAPEUTICS INC?
Ovid Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of medicines for patients and families living with rare neurological disorders. The company is headquartered in New York City, New York and currently employs 23 full-time employees. The company went IPO on 2017-05-05. The company is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. The company develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. The company also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
What is the current price of OVID stock?
The current stock price of OVID is 1.785 USD. The price increased by 0.28% in the last trading session.
Does OVID THERAPEUTICS INC pay dividends?
OVID does not pay a dividend.
What is the ChartMill technical and fundamental rating of OVID stock?
OVID has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists OVID stock?
OVID stock is listed on the Nasdaq exchange.
Can you provide the upcoming earnings date for OVID THERAPEUTICS INC?
OVID THERAPEUTICS INC (OVID) will report earnings on 2026-03-09, after the market close.
What is the outstanding short interest for OVID THERAPEUTICS INC?
The outstanding short interest for OVID THERAPEUTICS INC (OVID) is 5.82% of its float.
OVID Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to OVID. When comparing the yearly performance of all stocks, OVID is one of the better performing stocks in the market, outperforming 92.98% of all stocks.
OVID Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to OVID. OVID scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OVID Financial Highlights
Over the last trailing twelve months OVID reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS decreased by -6.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.9% | ||
| ROE | -81.28% | ||
| Debt/Equity | 0 |
OVID Forecast & Estimates
14 analysts have analysed OVID and the average price target is 4.23 USD. This implies a price increase of 137.14% is expected in the next year compared to the current price of 1.785.
For the next year, analysts expect an EPS growth of -22.94% and a revenue growth 896.44% for OVID